Indications
Kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (RCC): in combination with pembrolizumab, as first-line treatment (see section 5.1). in combination with everolimus, following one prior vascular endothelial growth factor (VEGF)-targeted therapy.
Composition
- Active substance
- lenvatinib mesilate
- International name (INN)
- lenvatinib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Kisplyx
- Active substance
- lenvatinib mesilate
- ATC code
- L01XE29
- Therapeutic area
- Carcinoma, Renal Cell